• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Virology Journal: A (H1N1) pdm09 HA D222 variants associated with severity and mortality in patients during a second wave in Mexico

tetano

Editor, Senior Moderator
A (H1N1) pdm09 HA D222 variants associated with severity and mortality in patients during a second wave in Mexico

Joel A Vazquez-Perez, Pavel Isa, Darwyn Kobasa, Christopher E Ormsby, Jose E Ram?rez-Gonzalez, Damaris P Romero-Rodr?guez, Charlene Ranadheera, Yan Li, Nathalie Bastien, Carissa Embury-Hyatt, Elizabeth Gonz?lez-Duran, Gisela Barrera-Badillo, Yuria Ablanedo-Terrazas, Edgar E Sevilla-Reyes, Marina Escalera-Zamudio, Ana G Cobi?n-G?emes, Irma Lopez, Joanna Ortiz-Alc?ntara, Celia Alpuche-Aranda, Jose R Perez-Padilla and Gustavo Reyes-Ter?n

For all author emails, please log on.

Virology Journal 2013, 10:41 doi:10.1186/1743-422X-10-41
Published: 31 January 2013
Abstract (provisional)
Background

Pandemic type A (H1N1) influenza arose in early 2009, probably in Mexico and the United States, and reappeared in North America in September for seven more months. An amino acid substitution in the hemagglutinin (HA), D222G, has been reported in a significant proportion of patients with a severe and fatal outcome. We studied the prevalence of HA222 substitutions in patients in Mexico during the second wave and its association with clinical outcome and pathogenicity in a mouse model.
Methods

The nucleotide sequences of hemagglutinin (HA) from viruses collected from 77 patients were determined including 50 severe and fatal cases and 27 ambulatory cases. Deep sequencing was done on 5 samples from severe or fatal cases in order to determine the quasispecies proportion. Weight loss and mortality due to infection with cultured influenza viruses were analyzed in a mouse model.
Results

Viruses from 14 out of 50 hospitalized patients (28%) had a non aspartic acid residue at the HA 222 position (nD222), while all 27 ambulatory patients had D222 (p = 0.0014). G222 was detected as sole species or in coexistence with N222 and D222 in 12 patients with severe disease including 8 who died. N222 in coexistence with D222 was detected in 1 patient who died and co-occurrence of A222 and V222, together with D222, was detected in another patient who died. The patients with a nD222 residue had higher mortality (71.4%), compared to the group with only D222 (22.2%, p = 0.0008). Four of the 14 viruses from hospitalized patients were cultured and intranasally infected into mice. Two viruses with G222 were lethal while a third virus, with G222, caused only mild illness in mice similar to the fourth virus that contained D222.
Conclusions

We confirm the elevated incidence of HA222 (H1N1)pdm09 variants in severe disease and mortality. Both clinical and mouse infection data support the idea that nD222 mutations contribute to increased severity of disease but additional determinants in disease outcome may be present.

full article

http://www.virologyj.com/content/pdf/1743-422X-10-41.pdf
 
Back
Top Bottom